Chinese herbal medicine for the treatment of primary hypertension: a methodology overview of systematic reviews

Systematic Reviews

Song Peng¹  Liu Bin¹  Sun Shaobo¹  Liu Kai¹  Li Yingdong²  Zhao Xinke²  Feng Mingxia³  Lu Yuqing³  Chen Kaibing³ 

[1] Key Lab of Prevention and Treatment for Chronic Disease by Traditional Chinese Medicine of Gansu Province;School of Basic Medical Sciences, Lanzhou University;The Hospital Affiliated to Gansu College of TCM;

关键词: Chinese herbal medicine;    Primary hypertension;    Overview;    GRADE;    Quality of evidence;    Methodological quality;   

DOI  :  10.1186/s13643-016-0353-y

来源: DOAJ

【 摘 要 】

Abstract Background Chinese herbal medicine has been used to treat hypertension in China and East Asia since centuries. In this study, we conduct an overview of systematic reviews of Chinese herbal medicine in the treatment of primary hypertension to 1) summarize the conclusions of these reviews, 2) evaluate the methodological quality of these reviews, and 3) rate the confidence in the effect on each outcome. Methods We comprehensively searched six databases to retrieve systematic reviews of Chinese herbal medicine for primary hypertension from inception to December 31, 2015. We used AMSTAR to evaluate the methodological quality of included reviews, and we classified the quality of evidence for each outcome in included reviews using the GRADE approach. Results A total of 12 systematic reviews with 31 outcomes were included, among which 11 systematic reviews focus on the therapeutic effect of Chinese herbal medicine combined with conventional medicine or simple Chinese herbal medicine versus simple conventional medicine. Among the 11 items of AMSTAR, the lowest quality was “providing a priori design” item, none review conformed to this item, the next was “stating the conflict of interest” item, only three reviews conformed to this item. Five reviews scored less than seven in AMSTAR, which means that the overall methodological quality was fairly poor. For GRADE, of the 31 outcomes, the quality of evidence was high in none (0 %), moderate in three (10 %), low in 19 (61 %), and very low in nine (29 %). Of the five downgrading factors, risk of bias (100 %) was the most common downgrading factor in the included reviews, followed by imprecision (42 %), inconsistency (39 %), publication bias (39 %), and indirectness (0 %). Conclusions The methodological quality of systematic reviews about Chinese herbal medicine for primary hypertension is fairly poor, and the quality of evidence level is low. Physicians should be cautious when applying the interventions in these reviews for primary hypertension patients in clinical practice.

【 授权许可】

Unknown